BETHLEHEM, Pa., Nov. 19, 2014 (GLOBE NEWSWIRE) -- CeGaT has been awarded second place in Deloitte's Technology Fast 50 Award business competition. Yesterday Managing Director Dr. Dirk Biskup accepted the award at the ceremony in Hamburg Emporio Tower.
The winners must have an above-average growth rate over the last five financial years, as well as a proprietary technology. The award of second place recognizes CeGaT as the second fastest growing company in Germany in 2014. When accepting the award, Dr. Dirk Biskup said, "In 2012 we already took the second place at the Fast 50 Award in the category 'Rising Star.' The fact that we were able to achieve the second place in the main category 'Technology Fast 50' is a great compliment to the excellence of our staff, without whom this success would not have been possible."
About B. Braun CeGaT, LLC
B. Braun CeGaT, established in 2014, is the result of a partnership between B. Braun, a leading provider of medical products and services, and the Center for Genomics and Transcriptomics (CeGaT), a Germany-based molecular diagnostic laboratory. The company, which shares its headquarters with B. Braun in Bethlehem, Pennsylvania, was formed to serve the US sequencing and diagnostics market by offering innovative molecular diagnostic services developed by CeGaT to US-based healthcare providers.
CeGaT has created and pioneered diagnostic panels for a wide range of disorders including cancer, epilepsy, neuromuscular disease, neurodegenerative disease, eye/vision-related disease, and more. This panel-based approach utilizes recent advancements in next generation sequencing technology, allowing for the simultaneous analysis of all genes associated with a particular disease. The information revealed by these tests can be used to identify the underlying cause of the disease in an individual patient and to help guide the course of treatment based on the patient's unique genetic profile.